Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8435746 | 0.98 | MKNK1 (0.39) | MKNK1SLC6A4SLC6A2SLC6A3DRD4 | |
| SCHEMBL17136283 | 0.87 | SLC6A2 (0.55) | SLC6A4SLC6A2SLC6A3KDM1ACHRNB2 | |
| SCHEMBL31192198 | 0.83 | GPR39 (0.43) | DRD4KDM1ANPC1ALDH1A1CYP2D6 | |
| SCHEMBL365267 | 0.83 | GPR39 (0.43) | DRD4KDM1ANPC1ALDH1A1CYP2D6 | |
| SCHEMBL10499108 | 0.83 | KDM1A (0.56) | SLC6A4SLC6A2KDM1A | |
| SCHEMBL17784680 | 0.80 | FFAR1 (0.44) | DRD4KDM1ANPC1ALDH1A1CYP2D6 | |
| SCHEMBL15130036 | 0.79 | CTSL (0.45) | NPC1 | |
| SCHEMBL13634315 | 0.77 | HRH3 (0.40) | MKNK1SLC6A4SLC6A2SLC6A3CHRNB2 | |
| SCHEMBL5513890 | 0.76 | HTR2C (0.42) | DRD4KDM1ANPC1ALDH1A1CYP2D6 | |
| SCHEMBL5513885 | 0.76 | HTR2C (0.42) | DRD4KDM1ANPC1ALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
| EP-4144735-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20220313676-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2022-10-06 | — | — | US | disclosed |
| CN-110177786-B | Substituted pyrazolo [1,5-A ] pyridine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2021-12-14 | — | — | CN | disclosed |
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200383966-A9 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-12-10 | — | — | US | disclosed |
| US-20200030311-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2020-01-30 | — | — | US | disclosed |
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-10-15 | — | — | US | disclosed |
| CN-110177786-A | Pyrazolo [1,5-A] pyridine compounds being substituted are as RET kinase inhibitor | 阿雷生物药品公司 | 2019-08-27 | — | — | CN | disclosed |
| EP-3523302-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2019-08-14 | — | — | EP | disclosed |
| US-20080027035-A1 | Dpp-Iv Inhibitors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2008-01-31 | — | — | US | disclosed |
| EP-1613304-B1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS CH (CH) | 2007-09-12 | — | — | EP | disclosed |
| EP-1613304-B1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS CH (CH) | 2007-09-12 | — | — | EP | disclosed |
| CN-1905868-A | DPP-IV inhibitors | GRAFFINITY PHARMACEUTICALS AG (CH) | 2007-01-31 | — | — | CN | disclosed |
| EP-1613304-A1 | DPP-IV INHIBITORS | Graffinity Pharmaceuticals Aktiengesellschaft (DE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2005056003-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005056003-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-06-23 | — | — | WO | disclosed |
| EP-0663912-A1 | HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION | ABBOTT LABORATORIES (US) | 1995-07-26 | — | — | EP | disclosed |
| EP-0663912-A4 | HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION. | ABBOTT LAB (US) | 1995-02-17 | — | — | EP | disclosed |
| WO-1994008992-A1 | HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION | ABBOTT LABORATORIES (US) | 1994-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027035-A1 | Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | MKNK1 3313/4885SLC6A4 294/4885SLC6A2 1121/4885 |
| US-20200383966-A9 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | MKNK1 198/4885SLC6A4 3586/4885SLC6A2 4053/4885 |
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | MKNK1 198/4885SLC6A4 3586/4885SLC6A2 4053/4885 |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | MKNK1 198/4885SLC6A4 3586/4885SLC6A2 4053/4885 |
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | MKNK1 198/4885SLC6A4 3586/4885SLC6A2 4053/4885 |
| US-20200030311-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | MKNK1 198/4885SLC6A4 3586/4885SLC6A2 4053/4885 |
| US-20220313676-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | MKNK1 198/4885SLC6A4 3586/4885SLC6A2 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.